CHMP to Assess Extended Indication of Kineret for COVID-19
Kineret (anakinra) is under evaluation by EMA's CHMP as a treatment for adult COVID-19 patients who are at an increased risk of severe respiratory failure.
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) is assessing data to evaluate whether Kineret (anakinra) can be used as a treatment for adult COVID-19 patients who are at an increased risk of severe respiratory failure.
Kineret is an immunosuppressant that has been authorized for use in the European Union for a number of inflammatory conditions since March 2002. It is believed that the API, anakinra, in Sobi’s Kineret could help reduce the inflammation and tissue damage associated with COVID-19. Anakinra works by blocking the activity of interleukin 1, which is a chemical messenger involved in immune processes that lead to inflammation.
Data from two ongoing clinical studies that are investigating the safety and efficacy of Kineret in adult patients hospitalized with COVID-19 are being evaluated by the CHMP. The committee’s opinion on whether or not Kineret’s indication can be extended will be forwarded to the European Commission, which will issue the final decision on marketing authorization for the European Union.
The outcome of the evaluation, which is expected to be released by October 2021, will be published by EMA.
Source: EMA
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
